The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI).

UNLABELLED An observational multicentric Italian trial on sentinel node biopsy (SNB) in melanoma patients was performed to diffuse a common SNB protocol nationwide (Italy). We report herein the results of this trial. The influence of some technical aspects on the outcome of SNB was also investigated, because a certain degree of variability was accepted in performing lymphoscintigraphy. METHODS From January 2000 to December 2002, 1,313 consecutive patients with primary cutaneous melanoma (Breslow thickness, >1.0 mm or <1.0 mm but with ulceration, Clark level IV-V, presence of regression) were enrolled by 23 centers. One half to 1 mL of 99mTc-labeled human albumin colloid, at a suggested dosage of 5-15 or 30-70 MBq, was injected intradermally, closely around the scar, the same day or the day before SNB. Intraoperatively, Patent blue was associated when a definitive wide excision of the primary was required. A positive sentinel node (SN) was defined when containing melanoma cells detected by either hematoxylin-eosin or immunohistochemistry (S100 and HMB45 antibodies). All patients underwent regular follow-up. False-negative cases were considered when lymph node metastases occurred in the same lymphatic basin of SN biopsy (SNB) during follow-up. A quality control program has been performed for the surgical procedure and for the histologic diagnosis. RESULTS The SN identification rate was 99.3%. The axilla was the site of the SN in 52.5% of the cases. The mean number of SNs was 2.0 (range, 1-17) and only 1 node was removed in 45.4%. The positivity and false-negative rates were 16.9% and 14.7%, respectively (median follow-up, 31 mo). On multivariate analysis (logistic and linear regression) only the number of peritumor injections was inversely associated with the number of excised SNs (P = 0.002), whereas none of the technical variables showed an independent impact on SN status when Breslow thickness was included as a control variable. CONCLUSION The number of peritumor injections seems to influence the outcome of lymphoscintigrapy in melanoma patients undergoing SNB. If these results are confirmed in a controlled trial, 3 injections at least should be recommended.

[1]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[2]  Natale Cascinelli,et al.  An Evidence‐based Staging System for Cutaneous Melanoma 1 , 2004, CA: a cancer journal for clinicians.

[3]  R. Scolyer,et al.  Sentinel node biopsy for melanoma: Where have we been and where are we going? , 2004, Annals of Surgical Oncology.

[4]  Jeremy MG Taylor,et al.  Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model , 2004, Annals of Surgical Oncology.

[5]  P. Erba,et al.  Radioguided sentinel lymph node biopsy in patients with malignant cutaneous melanoma: The nuclear medicine contribution , 2004, Journal of surgical oncology.

[6]  R. Turner,et al.  Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Scolyer,et al.  Pathologic Review of Negative Sentinel Lymph Nodes in Melanoma Patients With Regional Recurrence: A Clinicopathologic Study of 1152 Patients Undergoing Sentinel Lymph Node Biopsy , 2003, The American journal of surgical pathology.

[8]  A. Eggermont,et al.  The development of optimal pathological assessment of sentinel lymph nodes for melanoma , 2003, The Journal of pathology.

[9]  John F. Thompson,et al.  Patterns of lymphatic drainage from the skin in patients with melanoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  R. MacKie,et al.  The learning curve for sentinel node biopsy in malignant melanoma. , 2002, British journal of plastic surgery.

[11]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Ross,et al.  Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. , 2001, Surgery.

[13]  R. Turner,et al.  Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma , 2001, Cancer.

[14]  T. Smith,et al.  Gamma probe‐directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failures after long‐term follow‐up , 2001, Journal of surgical oncology.

[15]  O. Nieweg,et al.  Reproducibility of cutaneous lymphoscintigraphy: same or different lymphatic routes and sentinel nodes after reinjection? , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M. Gadd,et al.  Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study , 2001, Melanoma research.

[17]  Jonathan J. Lewis,et al.  Sentinel Lymph Node Biopsy in the Management of Patients With Primary Cutaneous Melanoma: Review of a Large Single-Institutional Experience With an Emphasis on Recurrence , 2001, Annals of surgery.

[18]  S. Muller,et al.  Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients , 2000, Annals of Surgical Oncology.

[19]  I. B. Borel Rinkes,et al.  Towards quality assurance of the sentinel node procedure in malignant melanoma patients: a single institution evaluation and a european survey , 1999, European Journal of Nuclear Medicine.

[20]  M. Ross,et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Liem,et al.  Reproducibility of lymphoscintigraphy for lymphatic mapping in cutaneous melanoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. Eshima,et al.  Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. , 1996, Radiology.

[23]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[24]  M. Wolter,et al.  THE LYMPHATICS OF THE SKIN , 1992 .

[25]  P. Mortimer,et al.  Lymphatics of the Skin , 1986, International journal of dermatology.

[26]  O. Nieweg,et al.  Review and Evaluation of Sentinel Node Procedures in 250 Melanoma Patients With a Median Follow-Up of 6 Years , 2003, Annals of Surgical Oncology.

[27]  J. V. Johannessen Cardiovascular system, lymphoreticular and hematopoietic system , 1980 .